Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Oncolytic HSV-1 rQNestin34.5v.2

Oncolytic virus · Kills target cells

Phase 1 Most advanced trial

1 Registered trials

What is Oncolytic HSV-1 rQNestin34.5v.2?

rQNestin34.5v.2 is an oncolytic herpes simplex virus-1 (HSV-1) vector administered by intratumoral injection. It is being studied in brain tumors including glioblastoma, astrocytoma, oligodendroglioma, and ependymoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: rQNestin
Drug type: Oncolytic virus
Mechanism: Kills target cells
Therapy area: Oncology
In trials of: CADL
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03152318	Phase 1	Malignant Glioma of Brain	Active not recruiting	CADL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anaplastic Oligodendroglioma of Brain (Diagnosis)AstrocytomaBrain CancerBrain TumorEpendymomaGangliogliomaGlioblastomaGlioblastoma MultiformeGliomaMalignant AstrocytomaMalignant Glioma of BrainMixed Oligo-AstrocytomaOligodendrogliomaPylocytic/Pylomyxoid Astrocytoma

Sources

ClinicalTrials.gov NCT03152318

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z